lead optimization

Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for the treatment of neuroinflammatory diseases including Multiple Sclerosis, Alzheimer's Disease, and brain bleeding events. The company is discovering and developing therapeutic compounds based on the apoE protein, small patented synthetic peptides of ten to seventeen amino acids with anti-inflammatory and neuroprotective activity. Cognosci purchased rights to an APOE-based compound from Duke University and has engineered over 500 new compounds.

clinical trial developmentcompound engineeringdrug discoverypreclinical development

Creative Scientist, Inc. develops customized New Approach Methodologies (NAMs), advanced human cell models, and scalable experimental platforms for drug discovery, efficacy assessment, safety evaluation, disease modeling, and mechanism-of-action studies. The company offers assay development, drug discovery and screening, drug safety and toxicology, disease modeling, advanced cell models, and molecular biology and analytical services. It also offers Volteer-96, an automated TEER measurement device, and VecStem endothelial cell culture media.

antibody-drug conjugatesantibody-RNA conjugatesassay developmentbarrier function assessmentcompound screeningcytotoxicity assessmentdisease modelingformulation stability testinghepatotoxicity assessmenthigh content imagingmechanism-of-action studiesparticle characterizationprotein expression and purificationTEER measurementvascular safety assessmentvirus-mediated gene delivery

Dauntless Biotherapeutics is a private preclinical oncology company led and advised by a team of researchers and industry veterans. It is developing an Antibody Drug Conjugate (ADC) to an undisclosed Tumor Associated Antigen (TAA) to treat cancers of unmet need, and is conducting a seed round to raise capital for lead optimization, in vivo, and non-GLP toxicity studies in preparation of an IND filing.

IND filing preparationin vivo studiesnon-GLP toxicity studies

ETAP-LAB is an independent preclinical CRO providing efficacy testing and preclinical pharmacology services to pharmaceutical, biotechnology and nutraceutical industries. Its services support drug discovery from in vitro lead optimization to non-GLP animal testing (POC, PK/PD, non-regulatory safety pharmacology) to assess efficacy and safety of drug candidates, medical devices and nutraceuticals. It has over 35 years of experience and is ISO 9001 certified (Nancy and Caen).

animal housingbrain-on-chiphigh content imaginghistologyimmunoassaysimmunofluorescenceimmunohistochemistryin vitro testingin vivo studiesmicrofluidicsPK/PDPOCpreclinical medical imagingpreclinical pharmacologysafety pharmacology